Completed PHASE1/PHASE2 INTERVENTIONAL 4-arm NCT02178670

Safety and Effectivity Immunotherapy to Treat Ovarian Cancer With Cancer Stem Cells Vaccine

Study of Cancer Stem Cell Vaccine That as a Specific Antigen in Metastatic Adenocarcinoma of the Ovarian

Sponsor: Fuda Cancer Hospital, Guangzhou

Interventions CSC-DC

Updated 6 times since 2017 Last updated: Sep 10, 2019 Started: Jun 30, 2014 Primary completion: Apr 30, 2015 Completion: Apr 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Neoplasms,Ovarian, this trial is completed. The trial is conducted by Fuda Cancer Hospital, Guangzhou and has accumulated 6 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Oct 2019 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Oct 2019 [monthly]

Completed PHASE1_PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

First recorded

Jun 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fuda Cancer Hospital, Guangzhou
University of Michigan

Data source: Fuda Cancer Hospital, Guangzhou

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China